Sun Pharma to buy U.S. drug firm Concert for $576 mn
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
sun pharma
January 2023
December 2022
November 2022
September 2022
July 2022
December 2021
November 2021
September 2019
November 2017
Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2%
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Sun Pharma Q2 profit rises 10.5% to ₹2,262 cr; revenue up 13%
Sun Pharma MD Dilip Shanghvi says in Q2, Sun Pharma recorded double-digit topline growth and strong margins, driven by market share gain in India, and sustained ramp-up of global specialty biz.
Surprise! Despite Covid-19 sales, Indian pharma an underperformer
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
Indian pharma majors to hit US growth bump in FY23
The revenue growth of about 16 leading Indian pharmaceutical companies is estimated to moderate to 6-7% in FY23, says ICRA.
Oral pills for Covid-19 by Sun Pharma, Cipla, Torrent & Strides
Sun Pharma will sell Molnupiravir under the brand name Molxvir in India, Torrent Pharma will sell it as Molnutor, while Cipla will market it as Cipmolnu.
AIRA Matrix — Dilip Shanghvi’s shot at drug discovery via AI
The company, set up and funded by Sun Pharma founder and MD Dilip Shanghvi’s family office, is focusing on AI-led pharma research and development, even offering tech tools to the industry for R&D.
Competitors Within
Home-grown smaller players are giving biggies a run for their money in the US generics market.
Healthcare spending to double by 2030: Bain report
Upper-middle-income households becoming the biggest demographic in 2030 will drive healthcare services.
Pharma stocks rise despite price fixing charges
The Nifty pharma index moved up sharply today, in what was a tepid trading day. The gains came as a surprise as top Indian companies faced new charges of price fixing in the US generic market.
